anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine pill of ease pill for benefiting liver and improving eyesight, which is prepared from the following raw materials in part by weight: the traditional Chinese medicine composition is prepared from 18 traditional Chinese medicines including angelica sinensis, white paeony root, radix bupleuri, codonopsis pilosula, loofah sponge, fructus liquidambaris, fructus aurantii, platycodon grandiflorum, chrysanthemum morifolium, fructus lycii, glossy privet fruit, poria cocos, bighead atractylodes rhizome, mint, honey-fried licorice root, folium mori, hairyvein agrimony, ligusticum wallichii and the like. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has the effects of regulating normal physiological function, protecting liver, benefiting liver, nourishing blood, improving eyesight, calming liver, dispelling pathogenic wind, nourishing yin, invigorating kidney, promoting fluid production, nourishing blood, dispelling pathogenic wind, clearing heat, harmonizing liver and spleen, recovering blurred vision, photophobia, lacrimation, and regulating physiological function of liver and kidney. 4. Can obviously improve the clinical symptoms and physical signs of patients and has the function of recovering the vision.
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis causing back pain, peripheral arthritis and enthesitis due to genetic background and autoimmunity. Patients with ankylosing spondylitis usually suffered from chronic pain over spine and peripheral joints since their second or third decades. It may also cause severe social and psychological burden to patients and their family.

Exercise and non-steroid anti-inflammatory drugs (NSAID) are the standard first-line treatments for AS（1）. Only 50% of patients with AS reach the ASAS response criteria（2） in clinical trials. Patients with severe disease activity should be put on disease-modifying anti-rheumatic drugs (DMARD), such as sulfasalazine（3） and anti-TNF biological agents. Add-on of acetaminophen and low dose anti-depressant （4）can slightly improve the response rate. However, there is no data if tramadol or ultracet can benefit AS.
1. The invention refers to reversible, time-limited tattooing. 2. The tattoo is produced on the human skin by means of natural or artificial UV radiation and pre-punched or self-designed special adhesive film or special stencils, with special light-stabilising adhesive spray, special light-stabilising paste and special light-stabilising cream. 3. The invention is designed primarily to stimulate the individual to think in terms of fashionable decoration. 4. All articles associated with the invention are medically tested and hence harmless to the human skin. 5. The invention can become a mass-produced fashion article, so that the purchase of the individual articles will be obligatory for each person.
Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still will require second or further lines for relapsed or refractory (rel/ref) disease. A small minority of these can be cured with standard chemoimmunotherapy/stem-cell transplant salvage approaches. CD19-directed chimeric antigen receptor T-cell (CAR-19) therapies are increasingly altering the prognostic landscape for rel/ref patients with DLBCL and related aggressive B-cell non-Hodgkin lymphomas. Long-term follow up data show ongoing disease-free outcomes consistent with cure in 30-40% after CAR-19, including high-risk patients primary refractory to or relapsing within 1 year of frontline treatment. This has made CAR-19 a preferred option for these difficult-to-treat populations. Widespread adoption, however, remains challenged by logistical and patient-related hurdles, including a requirement for certified tertiary care centers concentrated in urban centers, production times of at least 3-4 weeks, and high per-patients costs similar to allogeneic bone-marrow transplantation. Bispecific antibodies (BsAbs) are molecular biotherapies designed to bind and activate effector T-cells and drive them to B-cell antigens, leading to a similar cellular-dependent cytotoxicity as CAR-19. May and June of 2023 saw initial approvals of next-generation BsAbs glofitamab and epcoritamab in DLBCL as third or higher-line therapy, or for patients ineligible for CAR-19. BsAbs have similar spectrum but generally reduced severity of immune related side effects as CAR-19 and can be administered in community settings without need to manufacture patient-specific cellular products. To date and in contrast to CAR-19, however, there is no convincing evidence of cure after BsAbs monotherapy, though follow up is limited. The role of BsAbs in DLBCL treatment is rapidly evolving with trials investigating use in both relapsed and frontline curative-intent combinations. The future of DLBCL treatment is bound increasingly to include effector cell mediated immunotherapies, but further optimization of both cellular and BsAb approaches is needed.
Subjects will be randomized 1:1 to an experimental study group and a sham comparator (control) group.

Subjects in the experimental group will receive four (4) IPL treatments and meibomian gland expression (MGX) at 2-week intervals. IPL pulses will be administered on the skin of the malar region and below the lower eyelids. Following IPL therapy, subjects will undergo MGX of both eyelids in both eyes. Subjects in the control group will receive the same treatment (IPL followed by MGX), except that the IPL administration will be performed with the device off (sham treatment). Follow-up visits will occur at 1 month and 3 months after the final treatment session. At the follow-up, the changes in the outcome measures will be evaluated and compared between the two groups.
WARNING:

Thyroid hormones, including Levothyroxine sodium tablets, USP, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

Levothyroxine sodium should not be used in the treatment of male or female infertility unless this condition is associated with hypothyroidism. In patients with nontoxic diffuse goiter or nodular thyroid disease, particularly the elderly or those with underlying cardiovascular disease, levothyroxine sodium therapy is contraindicated if the serum TSH level is already suppressed due to the risk of precipitating overt thyrotoxicosis (see CONTRAINDICATIONS). If the serum TSH level is not suppressed, Levothyroxine sodium tablets, USP should be used with caution in conjunction with careful monitoring of thyroid function for evidence of hyperthyroidism and clinical monitoring for potential associated adverse cardiovascular signs and symptoms of hyperthyroidism.
Brain aging is compared between Cercopithecinae (macaques and baboons), non-human Hominidae (chimpanzees, orangutans, and gorillas), and their close relative, humans. β-amyloid deposition in the form of senile plaques (SPs) and cerebral β-amyloid angiopathy (CAA) is a frequent neuropathological change in non-human primate brain aging. SPs are usually diffuse, whereas SPs with dystrophic neurites are rare. Tau pathology, if present, appears later, and it is generally mild or moderate, with rare exceptions in rhesus macaques and chimpanzees. Behavior and cognitive impairment are usually mild or moderate in aged non-human primates. In contrast, human brain aging is characterized by early tau pathology manifested as neurofibrillary tangles (NFTs), composed of paired helical filaments (PHFs), progressing from the entorhinal cortex, hippocampus, temporal cortex, and limbic system to other brain regions. β-amyloid pathology appears decades later, involves the neocortex, and progresses to the paleocortex, diencephalon, brain stem, and cerebellum. SPs with dystrophic neurites containing PHFs and CAA are common. Cognitive impairment and dementia of Alzheimer's type occur in about 1-5% of humans aged 65 and about 25% aged 85. In addition, other proteinopathies, such as limbic-predominant TDP-43 encephalopathy, amygdala-predominant Lewy body disease, and argyrophilic grain disease, primarily affecting the archicortex, paleocortex, and amygdala, are common in aged humans but non-existent in non-human primates. These observations show that human brain aging differs from brain aging in non-human primates, and humans constitute the exception among primates in terms of severity and extent of brain aging damage.
NEW MATERIAL:Guanosine-metal chelate compounds of the formula (X is metal ion; when X is Al<3+> or Fe<3+>, m is 1-3, when X is Zn<2+>, Mg<2+> or Cu<2+> m is 2). EXAMPLE:Guanosine-zinc chelate compound. USE:The invention is chracterized by readily solubilizing guanosine that is hard soluble in water and ethanol. The solubility is further increased when the pH of the solvent is adjusted near 3.5 using vitamin C. The guanosine-aluminum chelate compound has unique gloss and is used as an additive for cosmetics. PREPARATION:Guanosine is made to react with a variety of metal salts in a solvent as water or ethanol to give the compound of the formula. The reaction temperature depends upon the kind of the solvent; however, preferably near the boiling point- at 100 deg.C.
Pathological femoral anteversion (FAV) or femoral maltorsion is often overlooked as a cause of anterior knee pain (AKP). Therefore, it should be routinely evaluated during physical examination of the patient with AKP. FAV is a problem because it changes the direction of the quadriceps and thereby the force acting on the patellofemoral joint. The Murphy CT method comes closest to showing the anatomical reality when FAV is evaluated. The treatment of choice in a patient with AKP with symptomatic excessive FAV is the femoral derotational osteotomy. Before doing a derotational osteotomy, the hip joint should be evaluated to avoid hip pain. Currently, no scientific evidence supports the cutoff point at which derotational femoral osteotomy should be the treatment of choice in young patients with AKP with symptomatic pathological FAV. Furthermore, no evidence exists regarding the level at which the osteotomy must be done.
Dentifrice compositions for mineralizing and remineralizing a surface or subsurface of at least one tooth, are described. The compositions primarily include at least one water soluble calcium salt, at least one water soluble phosphate salt, and at least one antioxidant, such as coenzyme Q10. Additionally, at least one water soluble non-toxic divalent metal compound, wherein the metal is other than calcium, such as magnesium, may also be added. Furthermore, at least one selenium-containing material, as well as at least one bromine-containing material, may also be added to the composition. The respective materials are then mixed and formed into a paste and applied to the tooth surface for a sufficient period of time to allow sufficient amounts of calcium and phosphate ions in the mixture to diffuse through the tooth surface, where the diffused ions react together to form an insoluble precipitate on the surface or subsurface of the tooth. The co-enzyme Q10, selenium, and bromine are believed to contribute to the overall health of the oval cavity, especially gum tissues.
In this single-center study, patients with suspected sepsis admitted to the Emergency Department at Södersjukhuset during a period of two years will be included. About 11,000 patients will be included. Patient data including described sepsis symptoms will be drawn from the electronic medical record, TakeCare and Clinisoft. Logistic regression analysis will adjust for age, gender, comorbidity according to Charlson score, vital signs, with preliminary focus of infection (pneumonia, urinary tract infection, abdominal, other, unknown). The Surviving Sepsis guidelines for the time period are: 3-hour bundle including lactate measurement, obtaining blood culture, fluid treatment if hypotensive and administration of broad-spectrum antibiotics. The 6-hour bundles with administration of vasopressors if needed, remeasure lactate if elevated, with persistent hypotension re-asses volume status and tissue perfusion. Time zero is defined as the admission time to the emergency department. The aim is to describe the association between adherence to treatment guidelines, gender, incidence and mortality for patients with sepsis.
OSA is an independent risk factor for a number of cardiovascular diseases. One important possible mechanism underlying cardiovascular disease in patients with OSA is systemic inflammation. CRP, an acute phase reactant secreted by the liver, is one of the most actively studied biomarkers of low-grade inflammation, and numerous studies have shown that higher CRP levels are associated with high mortality and morbidity due to cardiovascular disease in men and women. In patients with OSA, the question as to whether or not CRP levels are elevated is still under debate. Although continuous positive airway pressure (CPAP) is effective in the management of OSA, conflicting data also exist regarding the effects of CPAP on CRP levels. However, none of the existing studies assessed the influence of gender on the CRP evolution pattern. Therefore, the aim of this study was to investigate possible gender differences in CRP evolution in patients with moderate to severe OSA, free of medical comorbidities, 3 and 6 months after the start of effective CPAP treatment.
PURPOSE:To obtain a soft or a hard capsule simply producible at a low cost by stably encapsulating nicorandil useful as a therapeutic agent for angina pectoris with any of an oily base, a specific aqueous base and a powdery base. CONSTITUTION:This soft or hard capsule stably contains nicorandil, i.e. N-(2- hydroxyethyl)nicotinamide nitrate. The soft or hard capsule is obtained by mixing the nicorandil suspended or dissolved at 1-10wt.% concentration with an oily base and comprising the resultant mixture therein. Furthermore, a soft or a hard capsule is prepared by mixing the nicorandil similar to that used in the resultant soft or hard capsule with an aqueous base without affecting gelatin. The hard capsule is obtained from a mixture prepared from the nicorandil mixed at 0.1-10wt.% concentration and a powdery base. For example, corn oil is used as the oily base and, e.g. polyethylene glycol is used as the aqueous base. In addition, e.g. corn starch is used as the powdery base.
MARS, PAIS-SR and Patient Information Form, containing data about the patient and the disease were applied to each patient in the experimental group during pretest. Then, the individual training was given to each patient by giving the "Hypertension Training Booklet" prepared in line with the Roy Adaptation Model. The training period lasted for averagely 45-50 minutes for each patient. After the training, the patients were called by phone at least once a week, every week for four weeks and reminder information was obtained and their follow-ups were made. One month after the training, post-test data were applied to the patients. In the posttest phase; MARS, PAIS-SR and the questions containing lifestyle changes were repeated and their follow-ups were then terminated.
This study is a randomized controlled trial of 100 patients, who underwent history taking, physical examinations, x-rays, and MRI or ultrasonography, and were diagnosed with anterior cruciate ligament rupture from september 2023 to august 2028. The 100 patients will be assigned to Group I (with femoral nerve block) or Group II (without femoral nerve block) under double-blinded randomization. The randomization will be performed by an independent nurse using a computerized random sequence generator. The operators who participated in the procedure will be blinded to the participant's information. Both group will undergo general anesthesia for arthroscopic anterior cruciate ligament reconstruction. After anesthesia, sono-guided femoral nerve block will be performed. The injection for group1 is 20 mL ropivacaine and for groupII is 20 mL 0.9% saline. A visual analog scale (VAS) for pain will be recorded 1, 3, 6, 12, 18, 24, 36, 48 hours after the operation. VAS scores range from 0 to 10, with 0 being no pain and 10 being the most severe pain ever experienced. Injection with ultrasonography will be performed by a single anesthesiologist. 3 orthopedic surgeons will perform the surgery.
FIELD: cosmetology. SUBSTANCE: ascorbic acid, glycerol and a higher collagen concentration are used, 0.1-4.0% collagen is added and the mixture is allowed to swell for 24 hours. 0.4% sorbinic acid alcohol solution, 1.0-5.0% glycerol, 0.0125-0.0131 % dye and 0.5-1.5 % perfume additive are added while stirring. The agent is packed in dark glass flasks. EFFECT: improved skin elasticity and better properties of the agent components. 2 tbl
Participants assigned additional 3,000 steps/day on 5 days/week. Participants also received an additional 15 minutes of structured conversation with research personnel following the Health Action Process Approach Theory for behavior change.
This is a double blind, placebo controlled, randomised, phase 3 study. Patients that have been treated with Copaxone for at least 6 months at the screening visit will be randomised for treatment with simvastatin or placebo as an add-on to their Copaxone treatment. Patients will start treatment with 40 mg peroral simvastatin daily (or an apparently identical placebo) for one month. Hereafter, patients will escalate dosage to 80 mg daily. The patients will be examined clinically at screening, baseline and at 3, 6 and 12 months. Blood samples for immunology will be performed at baseline and at 1, 3, 6 and 12 months. Blood samples for safety assessments will be performed at all study visits. MRI will be performed (T1-weighted and T2-weighted) at baseline and at 6 and 12 months.
The clinical determination of the intravascular volume can be extremely difficult in critically ill patients. Although hemodynamic maximization was proposed, this approach was associated with a risk of fluid overload and excessive inotropic support. Therefore, fluid optimization was seen as a significant step forward and has been shown to decrease complications. Significant effort has been devoted to defining and developing simple means for predicting fluid responsiveness, i.e. whether the patient will benefit from fluid administration. Passive leg raising (PLR), a bedside performed test, could be used to accurately predict fluid responsiveness in most conditions.

However, most parameters that provide information about fluid responsiveness during volume expansion and PLR are invasive and time-consuming. A completely noninvasive and atraumatic parameter to predict fluid responsiveness might be need urgently. Transcutaneous partial pressure of oxygen (PtcO2), a measure to detect tissue ischemia or inadequate perfusion, might reflect the change in cardiac output, thus predict fluid responsiveness. The purpose of this study was to study the feasibility of predicting fluid responsiveness by transcutaneous partial pressure of oxygen in the critically ill patients.
Polynucleotide sequences which encode for human prepro insulin-like growth factors are provided. Such sequences are obtained from the human genome, typically by screening a cDNA library obtained from human liver cells. The polynucleotide sequences may be used for cloning and expression of insulin-like growth factors in suitable hosts, as well as for the production of DNA and RNA which may be used as hybridization probes. E. coli strains HB101(phigf1) and HB101(phigf2) were deposited at the ATCC on Jun. 8, 1984, and granted accession nos. 39729 and 39730, respectively.
The rectus femoris dry needling group will have their strength assessed. They will then receive one treatment of dry needling to a trigger point in their rectus femoris muscle. They will have their strength re-assessed 24, 48 \& 72 hours after dry needling.
NVDX3 implant is a sterilized, dry powder. The total administered quantity of NVDX3 implant depends on the bone defect size/intervertebral disc space.
Tyrosine kinase inhibitors (TKI) have introduced a significant advancement in cancer management. These compounds are administered orally, and their absorption holds a pivotal role in determining their variable efficacy. They exhibit extensive distribution within the body, binding strongly to both plasma and tissue proteins. Often reliant on efflux and influx transporters, TKI undergo primary metabolism by intestinal and hepatic cytochrome P450 enzymes, with nonkidney clearance being predominant. Owing to their limited therapeutic window, many TKI display considerable intraindividual and interindividual variability. This review offers a comprehensive analysis of the clinical pharmacokinetics of TKI, detailing their interactions with drug transporters and metabolic enzymes, while discussing potential clinical implications. The prevalence of kidney conditions, such as AKI and CKD, among patients with cancer is explored in their effect on TKI pharmacokinetics. Finally, the potential nephrotoxicity associated with TKI is also examined.
The patient information form, vital signs registration form, and state-trait anxiety scale were administered to the patients in the music group while they were in the ward before being sent to the CAG laboratory. Afterward, Rast, Acemasiran, and Huseyni music from Classical Turkish Music modes were optionally offered to the patients, and before the CAG procedure (while the patient was waiting for the procedure in the CAG laboratory), the music preferred by the patients was played with headphones for 15-20 minutes in order not to disturb other patients. After CAG, 15 minutes after the patient arrived at the service, he listened to music for 15-20 minutes. Then, the vital signs registration form, state-trait anxiety scale, Perianesthesia Comfort Scale-PCS" and Patient Satisfaction Survey on Nursing Care Quality (PSSNCQ) were applied.
Participants receive beltuzifan 120 mg orally QD and palbociclib orally QD in a 28-day schedule (21 days on followed by 7 days off), until progressive disease or discontinuation. Palbociclib will be administered at a dosage level determined in Part 1.
The invention discloses a DNA (deoxyribonucleic acid) vaccine of a HCV (hepatitis C virus) and a preparation method thereof, belonging to the field of molecular biology and infection immunity. The DNA vaccine is characterized in that that the second N-glycosylation site of HCV-E2 is mutated, that is, N423RT is mutated into D423RT. A nucleotide sequence of the mutant is shown in SEQIDNO.1. The DNA vaccine capable of generating the E2 mutant is obtained by introducing CpG sequences to the two terminals of an E2 gene and constructing mutated fragments onto a eukaryotic expression vector. The method is simple and convenient and is low in cost. The prepared DNA vaccine can induce stronger specific cellular immunity and neutralizing antibody than wild type HCVE2, enhance CD8+T specific killing activity, induce stronger IFN (interferon)-gamma and IL4 release and effectively neutralize further infection of the virus and overcomes the expression difficulty of glycosylated proteins.